Table S16: Characteristics of weighted populations in SIDIAP, database, stratified by staggered cohort and exposure status. Exposure is ChAdOx1 vaccine. Cohort 2 Cohort 3 Unvaccinated Vaccinated Vaccinated ASMD ASMD

Unvaccinated N (individuals) Age, median [Q25-Q75] Sex: Female, N(%) Years of prior history*, median [Q25-Q75] Number of GP visits, median [Q25-Q75] Number of PCR tests, median [Q25-Q75] Comorbidities**, N(%) 0.032 Anxiety 0.002 Asthma 0.006 Chronic kidney disease 0.005 COPD 0.000 Dementia 0.007 Depressive disorder 0.002 Diabetes 0.002 GERD 0.001 Heart failure 0.009 Hypertension 0.013 Hypothyroidism 0.030 Malignant neoplastic disease 0.003 Myocardial infarction 0.005 Osteoporosis 0.007 Pneumonia 0.021 Rheumatoid arthritis 0.006 Stroke 0.023 Venous thromboembolism The 4 cohorts represent vaccine rollout periods. *Calculated as the days of previous observation in the database before index date. **Assessed anytime before index date. ASMD = Absolute standardized mean difference, GP = General practice, PCR = Polymerase chain reaction, COPD = Chronic obstructive pulmonary disease, GERD = Gastro-Esophageal reflux disease 120,307 64 [61-66] 62,434 (52%) 15 [15-15] 2 [0-7] 0[0-0]

120,802 64 [61-66] 62,425 (52%) 15 [15-15] 4 [1-8] 0[0-0] 43,901 64 [61-67] 22,980 (52%) 15 [15-15] 2 [0-7] 0[0-0] 44,033 64 [61-66] 23,009 (52%) 15 [15-15] 2 [0-7] 0[0-0] 0.002 0.002 0.005 0.003 0.005 0.000 0.004 0.003 0.017 0.013 9,717 (22%) 1,639 (4%) 1,597 (4%) 2,350 (5%) 171 (0%) 5,813 (13%) 5,705 (13%) 3,216 (7%) 847 (2%) 13,737 (31%) 3,830 (9%) 3,910 (9%) 868 (2%) 2,200 (5%) 2,167 (5%) 259 (1%) 1,000 (2%) 541 (1%) 0.007 0.006 0.005 0.004 0.010 0.007 0.005 0.002 0.003 0.001 0.005 0.007 0.004 0.001 0.003 0.008 0.007 0.016 27,989 (23%) 4,785 (4%) 4,526 (4%) 6,846 (6%) 397 (0%) 16,258 (13%) 16,418 (14%) 9,569 (8%) 2,236 (2%) 39,551 (33%) 11,173 (9%) 12,418 (10%) 2,500 (2%) 6,679 (6%) 6,392 (5%) 931 (1%) 2,582 (2%) 1,469 (1%) 28,213 (23%) 4,909 (4%) 4,390 (4%) 6,702 (6%) 470 (0%) 16,483 (14%) 16,127 (13%) 9,580 (8%) 2,268 (2%) 39,422 (33%) 10,965 (9%) 12,621 (10%) 2,553 (2%) 6,687 (6%) 6,452 (5%) 1,009 (1%) 2,693 (2%) 1,686 (1%)

10,333 (23%) 1,664 (4%) 1,556 (4%) 2,405 (5%) 170 (0%) 5,940 (13%) 5,698 (13%) 3,206 (7%) 844 (2%) 13,589 (31%) 4,002 (9%) 4,304 (10%) 888 (2%) 2,155 (5%) 2,243 (5%) 337 (1%) 965 (2%) 659 (1%) 41 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any relianceSupplemental materialplaced on this supplemental material which has been supplied by the author(s)Heart doi: 10.1136/heartjnl-2023-3234839.:10 2024;Heart, et al. Mercad-Besora N 42 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any relianceSupplemental materialplaced on this supplemental material which has been supplied by the author(s)Heart doi: 10.1136/heartjnl-2023-3234839.:10 2024;Heart, et al. Mercad-Besora N Table S17: Characteristics of unweighted populations in SIDIAP, database, stratified by staggered cohort and exposure status. Exposure is ChAdOx1 vaccine. Cohort 2 Cohort 3 Unvaccinated Vaccinated Vaccinated ASMD ASMD